Susanna Margaretha H. Kannenberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Susanna Margaretha H. Kannenberg has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Willem Izak Visser
Division of Dermatology, Department of Medicine, Faculty of Medicine and Health Sciences Stellenbosch University Cape Town South Africa
3 shared publications A J Arendse
5th-year medical student, Division of Dermatology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
1 shared publication- Ahmed I. Manjra
Hiway Medical Centre, Westville Hospital, Durban, South Africa
1 shared publication Alaa Masri
AbbVie BioPharmaceuticals GmBH, Dubai, United Arab Emirates
1 shared publicationAlejandra Piegari Feliu
CIREC LATAM Buenos Aires Argentina
1 shared publicationAleksandra Lesiak
Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland
1 shared publication
Latest Publications
- Open Access
- 25 July 2026
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 42 (4) , e70112
Beyond Tint: Active Ingredient Strategies for Post‐Inflammatory Hyperpigmentation due to Visible Light in Skin of Color
Background: Post‐inflammatory hyperpigmentation (PIH) is among the most burdensome sequelae of inflammatory dermatoses in skin of color (SOC), and reduction of visible pigmentation represents the primary clinical outcome of interest. Tinted sunscreens containing iron oxides and/or pigmentary titanium dioxide are currently the best‐evidenced strategy for preventing visible light–driven PIH in SOC. However, cosmetic unacceptability—including white cast, poor shade match, and texture incompatibility with acne‐prone skin—significantly limits real‐world adherence. This concept paper proposes a clinical reframing: when pigment‐based visible light filters are not tolerated, pigmentation reduction may be achievable through proactive topical actives with direct anti‐pigmentation activity. Methods: This commentary synthesizes the mechanistic and clinical literature on high‐energy visible light (HEVL)–driven pigmentation in SOC, with particular focus on the opsin‐3–MITF–melanogenesis axis and topical actives with demonstrated anti‐pigmentation activity against HEVL‐induced melanogenesis. Evidence is presented to support a proposed clinical reframing and pragmatic algorithm. Results: HEVL activates opsin‐3 on melanocytes, upregulating MITF and promoting formation of stable, autophagy‐resistant melanosomes—a mechanism distinct from UVA‐driven photooxidation and particularly relevant in darker phototypes. Four prototypical actives with direct clinical or preclinical evidence against HEVL‐induced pigmentation are reviewed. Conclusion: Pigmentation reduction—rather than the mechanism by which it is achieved—should be recognized as the primary clinical endpoint in photoprotection for PIH in SOC. When pigment‐based visible light filters containing iron oxides and/or pigmentary titanium dioxide are cosmetically unacceptable, a strategy combining broad‐spectrum UVA1 photoprotection with a topical active with anti‐pigmentation activity represents a rational, evidence‐informed alternative that keeps the clinical goal firmly in focus.
- 25 July 2026
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 42 (4) , e70112
Open AccessBeyond Tint: Active Ingredient Strategies for Post‐Inflammatory Hyperpigmentation due to Visible Light in Skin of Color
Background: Post‐inflammatory hyperpigmentation (PIH) is among the most burdensome sequelae of inflammatory dermatoses in skin of color (SOC), and reduction of visible pigmentation represents the primary clinical outcome of interest. Tinted sunscreens containing iron oxides and/or pigmentary titanium dioxide are currently the best‐evidenced strategy for preventing visible light–driven PIH in SOC. However, cosmetic unacceptability—including white cast, poor shade match, and texture incompatibility with acne‐prone skin—significantly limits real‐world adherence. This concept paper proposes a clinical reframing: when pigment‐based visible light filters are not tolerated, pigmentation reduction may be achievable through proactive topical actives with direct anti‐pigmentation activity. Methods: This commentary synthesizes the mechanistic and clinical literature on high‐energy visible light (HEVL)–driven pigmentation in SOC, with particular focus on the opsin‐3–MITF–melanogenesis axis and topical actives with demonstrated anti‐pigmentation activity against HEVL‐induced melanogenesis. Evidence is presented to support a proposed clinical reframing and pragmatic algorithm. Results: HEVL activates opsin‐3 on melanocytes, upregulating MITF and promoting formation of stable, autophagy‐resistant melanosomes—a mechanism distinct from UVA‐driven photooxidation and particularly relevant in darker phototypes. Four prototypical actives with direct clinical or preclinical evidence against HEVL‐induced pigmentation are reviewed. Conclusion: Pigmentation reduction—rather than the mechanism by which it is achieved—should be recognized as the primary clinical endpoint in photoprotection for PIH in SOC. When pigment‐based visible light filters containing iron oxides and/or pigmentary titanium dioxide are cosmetically unacceptable, a strategy combining broad‐spectrum UVA1 photoprotection with a topical active with anti‐pigmentation activity represents a rational, evidence‐informed alternative that keeps the clinical goal firmly in focus.
- Open Access
- 29 May 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (6)
Evaluation of a Dermocosmetic Serum for Managing Hyperpigmentation Disorders in Phototypes IV ‐ VI Individuals From South Africa and Argentina
Background: Hyperpigmentation disorders are a distressing condition, especially for individuals with skin of color who are at higher risk. Often treated topically, a significant advancement in this field was Kligman's depigmenting trio, inhibiting melanogenesis, providing anti‐inflammatory benefits, and promoting epidermal renewal. Aims: Evaluate a serum (Pigmentbio C‐Concentrate, NAOS, LABORATOIRE BIODERMA), inspired by Kligman's trio's mode of action. Methods: Clinical studies were conducted on phototype IV–VI subjects in South Africa and Argentina. Subjects applied the serum nightly for 84 days. Clinical assessments were performed on days 0, 28, 56, and 84, with instrumental skin color evaluation in Argentina. The burden of hyperpigmentation was assessed at baseline and D84 using the Dermatology Life Quality Index (DLQI, South Africa) or the Melasma Quality of Life Questionnaire (MELASQoL, Argentina). Results: In South Africa, clinical assessments showed a significant reduction in the number (−15%), intensity (−32%), and size (−13%) of hyperpigmented elements within 28 days. The Argentinian study similarly reported significantly decreased intensity (−18%), visibility (−32%), and contrast (−29%) of hyperpigmented elements on D28, alongside improved complexion homogeneity (+17%). In both studies, maximum improvements occurred on D84. These results were supported by instrumental assessments of skin luminance and pigmentation of hyperpigmented areas (L*: +5%, ITA°: +53% on D84), and color difference between hyperpigmented and non‐hyperpigmented areas (∆E: −16% on D84). Participants also reported a reduced burden of hyperpigmentation (DLQI: −92%; MELASQoL: −33%). Conclusion: Replicating the complementary activities of Kligman's trio, the serum effectively reduces hyperpigmentation and its associated burden in individuals with darker phototypes.
- 29 May 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (6)
Open AccessEvaluation of a Dermocosmetic Serum for Managing Hyperpigmentation Disorders in Phototypes IV ‐ VI Individuals From South Africa and Argentina
Background: Hyperpigmentation disorders are a distressing condition, especially for individuals with skin of color who are at higher risk. Often treated topically, a significant advancement in this field was Kligman's depigmenting trio, inhibiting melanogenesis, providing anti‐inflammatory benefits, and promoting epidermal renewal. Aims: Evaluate a serum (Pigmentbio C‐Concentrate, NAOS, LABORATOIRE BIODERMA), inspired by Kligman's trio's mode of action. Methods: Clinical studies were conducted on phototype IV–VI subjects in South Africa and Argentina. Subjects applied the serum nightly for 84 days. Clinical assessments were performed on days 0, 28, 56, and 84, with instrumental skin color evaluation in Argentina. The burden of hyperpigmentation was assessed at baseline and D84 using the Dermatology Life Quality Index (DLQI, South Africa) or the Melasma Quality of Life Questionnaire (MELASQoL, Argentina). Results: In South Africa, clinical assessments showed a significant reduction in the number (−15%), intensity (−32%), and size (−13%) of hyperpigmented elements within 28 days. The Argentinian study similarly reported significantly decreased intensity (−18%), visibility (−32%), and contrast (−29%) of hyperpigmented elements on D28, alongside improved complexion homogeneity (+17%). In both studies, maximum improvements occurred on D84. These results were supported by instrumental assessments of skin luminance and pigmentation of hyperpigmented areas (L*: +5%, ITA°: +53% on D84), and color difference between hyperpigmented and non‐hyperpigmented areas (∆E: −16% on D84). Participants also reported a reduced burden of hyperpigmentation (DLQI: −92%; MELASQoL: −33%). Conclusion: Replicating the complementary activities of Kligman's trio, the serum effectively reduces hyperpigmentation and its associated burden in individuals with darker phototypes.
- Open Access
- 13 February 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (2) , e70696
Dermocosmetics in Acne Vulgaris: South African Consensus Recommendations With a Focus on Skin of Color
Background: Acne vulgaris is one of the most common dermatological disorders worldwide, affecting both adolescents and adults. It frequently leads to significant psychosocial and physical sequelae, including acne‐induced hyperpigmentation and scarring. Beyond pharmaceutical therapies, dermocosmetics—topical formulations enriched with active ingredients in cosmetically elegant vehicles—have emerged as essential partners in acne management. They optimize clinical outcomes by supporting skin barrier repair, reducing irritation associated with conventional treatments, and targeting key pathogenic pathways in acne. However, no region‐specific guidance exists to inform the effective use of dermocosmetics in South African patients, particularly those with skin of color. Aims: To develop expert consensus recommendations for the use of dermocosmetics in acne vulgaris management within the South African context. Methods: This consensus was developed through structured expert meetings and a targeted literature review of current international and local evidence. The panel synthesized clinical experience and research findings to identify key principles for selecting and integrating dermocosmetics into acne treatment regimens. Results: The consensus highlights the multifaceted role of dermocosmetics in addressing core acne pathogenic factors, supporting epidermal barrier function, mitigating treatment‐related adverse effects, and managing acne‐induced hyperpigmentation in skin of color. Practical recommendations are provided for their use as adjunctive therapy, monotherapy in mild cases, and maintenance therapy to sustain remission. Conclusion: This South African consensus provides a practical, evidence‐informed framework for incorporating dermocosmetics into acne management, with particular attention to the needs of patients with skin of color. Adoption of these recommendations may enhance treatment outcomes, adherence, and patient satisfaction across diverse skin types.
- 13 February 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (2) , e70696
Open AccessDermocosmetics in Acne Vulgaris: South African Consensus Recommendations With a Focus on Skin of Color
Background: Acne vulgaris is one of the most common dermatological disorders worldwide, affecting both adolescents and adults. It frequently leads to significant psychosocial and physical sequelae, including acne‐induced hyperpigmentation and scarring. Beyond pharmaceutical therapies, dermocosmetics—topical formulations enriched with active ingredients in cosmetically elegant vehicles—have emerged as essential partners in acne management. They optimize clinical outcomes by supporting skin barrier repair, reducing irritation associated with conventional treatments, and targeting key pathogenic pathways in acne. However, no region‐specific guidance exists to inform the effective use of dermocosmetics in South African patients, particularly those with skin of color. Aims: To develop expert consensus recommendations for the use of dermocosmetics in acne vulgaris management within the South African context. Methods: This consensus was developed through structured expert meetings and a targeted literature review of current international and local evidence. The panel synthesized clinical experience and research findings to identify key principles for selecting and integrating dermocosmetics into acne treatment regimens. Results: The consensus highlights the multifaceted role of dermocosmetics in addressing core acne pathogenic factors, supporting epidermal barrier function, mitigating treatment‐related adverse effects, and managing acne‐induced hyperpigmentation in skin of color. Practical recommendations are provided for their use as adjunctive therapy, monotherapy in mild cases, and maintenance therapy to sustain remission. Conclusion: This South African consensus provides a practical, evidence‐informed framework for incorporating dermocosmetics into acne management, with particular attention to the needs of patients with skin of color. Adoption of these recommendations may enhance treatment outcomes, adherence, and patient satisfaction across diverse skin types.
- Open Access
- 3 October 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (1) , 125-134
Skin disease in the Eastern Cape (SKINSCAPE): a Global Psoriasis Atlas point prevalence study in rural South Africa
Background: The Eastern Cape is an under-resourced province and the poorest in South Africa, where little is known about the epidemiology of skin diseases. Objectives: To examine the nature and prevalence of skin diseases in two neighbouring rural villages in the Eastern Cape, South Africa. Methods: We conducted a cross-sectional point prevalence study of skin diseases of residents (adults and children) in Mtyholo Dlova and Mdolomba villages in December 2023. Through house-to-house visits, we collected data on the households, participant demographics and skin diagnoses following clinical skin examination by dermatologists. Point prevalence rates and 95% confidence intervals (CIs) were calculated for each skin condition. Results: A total of 309 households were visited with 698 participants included of whom 99% were Xhosa people, 56% were female [mean (SD) age 37.4 (24.2) years], 39% were unemployed, 18% were retired, 60% did not smoke and 69% did not drink alcohol. Seventy-five per cent of households had an average monthly income < ZAR3000 South African Rand (128 GBP). In total, 439 people had at least one skin disease with a point prevalence of any skin disease of 62.9% (95% CI 59.3–66.5). The most prevalent diseases in children (aged < 18 years) were tinea capitis (16.4%), acne vulgaris (13.0%), pityriasis alba (10.6%), prurigo (4.8%), postinflammatory hyperpigmentation (3.9%), xerosis (3.9%), atopic dermatitis (3.4%) and scabies (3.4%). In adults, the most prevalent diseases were xerosis (7.8%), acne vulgaris (7.4%), melasma (6.2%), dermatosis papulosa nigra (5.6%), scarring alopecia (3.5%), nonscarring alopecia (3.1%) and tinea pedis (3.1%). Psoriasis was rare, with a prevalence of 0.3% in the study population. Generally, skin disease was more common in female than male participants (65.8% vs. 59.2%) with sex-specific differences in the prevalence of certain dermatoses; melasma, alopecia (scarring and nonscarring), seborrhoeic dermatitis, dermatosis papulosa nigra and irritant contact dermatitis were more prevalent in female participants, whereas there was a predominance of pseudofolliculitis barbae, atopic dermatitis, postinflammatory hyperpigmentation, acne vulgaris, pityriasis versicolor, scabies, tinea pedis and tinea capitis in male participants. Conclusions: Skin disease is common in the Eastern Cape, South Africa. These findings may help strengthen the provision of dermatology services and the distribution of resources in the region, and highlight training opportunities for healthcare workers.
- 3 October 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (1) , 125-134
Open AccessSkin disease in the Eastern Cape (SKINSCAPE): a Global Psoriasis Atlas point prevalence study in rural South Africa
Background: The Eastern Cape is an under-resourced province and the poorest in South Africa, where little is known about the epidemiology of skin diseases. Objectives: To examine the nature and prevalence of skin diseases in two neighbouring rural villages in the Eastern Cape, South Africa. Methods: We conducted a cross-sectional point prevalence study of skin diseases of residents (adults and children) in Mtyholo Dlova and Mdolomba villages in December 2023. Through house-to-house visits, we collected data on the households, participant demographics and skin diagnoses following clinical skin examination by dermatologists. Point prevalence rates and 95% confidence intervals (CIs) were calculated for each skin condition. Results: A total of 309 households were visited with 698 participants included of whom 99% were Xhosa people, 56% were female [mean (SD) age 37.4 (24.2) years], 39% were unemployed, 18% were retired, 60% did not smoke and 69% did not drink alcohol. Seventy-five per cent of households had an average monthly income < ZAR3000 South African Rand (128 GBP). In total, 439 people had at least one skin disease with a point prevalence of any skin disease of 62.9% (95% CI 59.3–66.5). The most prevalent diseases in children (aged < 18 years) were tinea capitis (16.4%), acne vulgaris (13.0%), pityriasis alba (10.6%), prurigo (4.8%), postinflammatory hyperpigmentation (3.9%), xerosis (3.9%), atopic dermatitis (3.4%) and scabies (3.4%). In adults, the most prevalent diseases were xerosis (7.8%), acne vulgaris (7.4%), melasma (6.2%), dermatosis papulosa nigra (5.6%), scarring alopecia (3.5%), nonscarring alopecia (3.1%) and tinea pedis (3.1%). Psoriasis was rare, with a prevalence of 0.3% in the study population. Generally, skin disease was more common in female than male participants (65.8% vs. 59.2%) with sex-specific differences in the prevalence of certain dermatoses; melasma, alopecia (scarring and nonscarring), seborrhoeic dermatitis, dermatosis papulosa nigra and irritant contact dermatitis were more prevalent in female participants, whereas there was a predominance of pseudofolliculitis barbae, atopic dermatitis, postinflammatory hyperpigmentation, acne vulgaris, pityriasis versicolor, scabies, tinea pedis and tinea capitis in male participants. Conclusions: Skin disease is common in the Eastern Cape, South Africa. These findings may help strengthen the provision of dermatology services and the distribution of resources in the region, and highlight training opportunities for healthcare workers.
- Open Access
- 4 May 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (5) , 1173-1187
Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From the ESSENTIAL AD Multicountry Study
Introduction Limited real-world evidence exists about the burden of atopic dermatitis (AD) in patients receiving systemic or non-systemic therapies in clinical practices. ESSENTIAL AD was an observational study that aimed to fill this information gap. Methods ESSENTIAL AD enrolled (September 2021–June 2022) adult patients with physician-confirmed AD that was routinely managed with systemic and non-systemic treatment in a real-world setting from 15 countries in Eastern Europe, the Middle East, and Africa. Primary outcome variables were Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), and Dermatology Life Quality Index (DLQI) assessed during one office visit. Results A total of 799 enrolled patients fulfilled selection criteria and were included in the study. Patients mean (standard deviation [SD]) age was 36.3 (14.4) years, 457 (57.2%) were female, and the majority of patients were white (647 [81.0%]). Mean (SD) time since AD diagnosis was 17.6 (15.2) years (median 16.5; interquartile range [IQR] 3.3–26.8). The mean (SD) EASI, SCORAD, and DLQI total scores were 11.3 (11.3 [median 8.1; IQR 3.6–15.8]), 37.8 (17.9 [median 35.5; IQR 24.2–49.0]), and 10.6 (7.2 [median 10.0; IQR 5.0–15.0]), respectively. Patients receiving systemic treatment had significantly higher disease burden (mean [SD] EASI 13.3 [13.0]; median [IQR] 9.6 [3.9–17.9]) versus non-systemic treatment (mean [SD] 9.3 [8.7]; median [IQR] 6.8 [3.0–13.2]; P < 0.0001). Results were similar for SCORAD (39.9 [19.6] vs 35.6 [15.7]; median [IQR] 38.6 [24.7–53.1] vs 32.6 [23.9–44.6]; P = 0.0017), and DLQI total scores (11.4 [7.4] vs 9.9 [6.9]; median [IQR] 11.0 [5.0–16.0] vs 9.0 [5.0–14.0]; P = 0.0033, respectively). Conclusion Patients with AD continue to have substantial disease burden despite treatment with systemic therapy, suggesting that a need for effective disease management remains, including effective therapies that improve psychological outcomes and reduce economic burden of AD, in Eastern Europe, the Middle East, and Africa.
- 4 May 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (5) , 1173-1187
Open AccessReal-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From the ESSENTIAL AD Multicountry Study
Introduction Limited real-world evidence exists about the burden of atopic dermatitis (AD) in patients receiving systemic or non-systemic therapies in clinical practices. ESSENTIAL AD was an observational study that aimed to fill this information gap. Methods ESSENTIAL AD enrolled (September 2021–June 2022) adult patients with physician-confirmed AD that was routinely managed with systemic and non-systemic treatment in a real-world setting from 15 countries in Eastern Europe, the Middle East, and Africa. Primary outcome variables were Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), and Dermatology Life Quality Index (DLQI) assessed during one office visit. Results A total of 799 enrolled patients fulfilled selection criteria and were included in the study. Patients mean (standard deviation [SD]) age was 36.3 (14.4) years, 457 (57.2%) were female, and the majority of patients were white (647 [81.0%]). Mean (SD) time since AD diagnosis was 17.6 (15.2) years (median 16.5; interquartile range [IQR] 3.3–26.8). The mean (SD) EASI, SCORAD, and DLQI total scores were 11.3 (11.3 [median 8.1; IQR 3.6–15.8]), 37.8 (17.9 [median 35.5; IQR 24.2–49.0]), and 10.6 (7.2 [median 10.0; IQR 5.0–15.0]), respectively. Patients receiving systemic treatment had significantly higher disease burden (mean [SD] EASI 13.3 [13.0]; median [IQR] 9.6 [3.9–17.9]) versus non-systemic treatment (mean [SD] 9.3 [8.7]; median [IQR] 6.8 [3.0–13.2]; P < 0.0001). Results were similar for SCORAD (39.9 [19.6] vs 35.6 [15.7]; median [IQR] 38.6 [24.7–53.1] vs 32.6 [23.9–44.6]; P = 0.0017), and DLQI total scores (11.4 [7.4] vs 9.9 [6.9]; median [IQR] 11.0 [5.0–16.0] vs 9.0 [5.0–14.0]; P = 0.0033, respectively). Conclusion Patients with AD continue to have substantial disease burden despite treatment with systemic therapy, suggesting that a need for effective disease management remains, including effective therapies that improve psychological outcomes and reduce economic burden of AD, in Eastern Europe, the Middle East, and Africa.
- Open Access
- 3 November 2020
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 110 (12) , 1148
COVID-19 collateral damage: Alcohol rub dermatitis as an emerging problem
COVID-19 collateral damage: Alcohol rub dermatitis as an emerging problem
- 3 November 2020
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 110 (12) , 1148
Open AccessCOVID-19 collateral damage: Alcohol rub dermatitis as an emerging problem
COVID-19 collateral damage: Alcohol rub dermatitis as an emerging problem
- Open Access
- 16 January 2020
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 21 (1)
The prevalence and spectrum of mucocutaneous disease in South African people living with HIV and accessing care at a district-level hospital
Background: Although the association between human immunodeficiency virus (HIV) and mucocutaneous diseases has been well studied within South African specialist centres, there is limited data from district-level hospitals. Available data may, therefore, fail to reflect the prevalence and full spectrum of dermatoses seen in people living with HIV (PLWH).Objectives: To determine the prevalence and spectrum of dermatoses seen in PLWH.Method: We conducted a cross-sectional, descriptive study of 970 PLWH (men and women, ≥ 18 years old) accessing care at Karl Bremer Hospital, a district-level hospital located in the Western Cape province, South Africa, between 01 September 2016 and 28 February 2017.Results: The prevalence of mucocutaneous disease in this sample was 12.7% (95% confidence interval [CI] 0.11–0.15). Non-infectious dermatoses comprised 71.0% of the disorders. Pruritic papular eruption (20.0%) and seborrheic dermatitis (6.0%) were the most common non-infectious dermatoses. Tinea corporis (8.0%) and oral candidiasis (6.0%) were the most prevalent infectious dermatoses. There was no significant association between skin disease category (infectious or non-infectious dermatoses) and patient demographics (gender and ethnicity) or HIV-disease characteristics (CD4+ cell count, viral load and duration of antiretroviral therapy [ART]).Conclusion: This study provides valuable scientific data on the prevalence and spectrum of mucocutaneous disease in PLWH attending a South African district-level hospital. Prospective studies conducted in other district-level centres across the country are required to determine the lifetime prevalence and spectrum of dermatoses in PLWH in the ART era.
- 16 January 2020
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 21 (1)
Open AccessThe prevalence and spectrum of mucocutaneous disease in South African people living with HIV and accessing care at a district-level hospital
Background: Although the association between human immunodeficiency virus (HIV) and mucocutaneous diseases has been well studied within South African specialist centres, there is limited data from district-level hospitals. Available data may, therefore, fail to reflect the prevalence and full spectrum of dermatoses seen in people living with HIV (PLWH).Objectives: To determine the prevalence and spectrum of dermatoses seen in PLWH.Method: We conducted a cross-sectional, descriptive study of 970 PLWH (men and women, ≥ 18 years old) accessing care at Karl Bremer Hospital, a district-level hospital located in the Western Cape province, South Africa, between 01 September 2016 and 28 February 2017.Results: The prevalence of mucocutaneous disease in this sample was 12.7% (95% confidence interval [CI] 0.11–0.15). Non-infectious dermatoses comprised 71.0% of the disorders. Pruritic papular eruption (20.0%) and seborrheic dermatitis (6.0%) were the most common non-infectious dermatoses. Tinea corporis (8.0%) and oral candidiasis (6.0%) were the most prevalent infectious dermatoses. There was no significant association between skin disease category (infectious or non-infectious dermatoses) and patient demographics (gender and ethnicity) or HIV-disease characteristics (CD4+ cell count, viral load and duration of antiretroviral therapy [ART]).Conclusion: This study provides valuable scientific data on the prevalence and spectrum of mucocutaneous disease in PLWH attending a South African district-level hospital. Prospective studies conducted in other district-level centres across the country are required to determine the lifetime prevalence and spectrum of dermatoses in PLWH in the ART era.
- Open Access
- 1 January 2020
- Published by AOSIS in South African Family Practice
- Vol. 62 (1) , 9-e9
Paediatric atopic eczema (atopic dermatitis) in South Africa: A practical algorithm for the management of mild-to-moderate disease in daily clinical practice
Background: Atopic eczema (AE) is a chronic, highly pruritic, inflammatory skin condition with increasing prevalence worldwide. Atopic eczema mostly affects children, impairing quality of life with poor disease control leading to progression of other atopic disorders. As most patients in South Africa have no access to specialist healthcare, a practical approach is needed for the management of mild-to-moderate AE in paediatric patients for daily clinical practice. Methods: A panel of experts in AE convened to develop a practical algorithm for the management of AE for children and adolescents in South Africa. Results: Regular moisturising with an oil-based emollient remains the mainstay of AE treatment. Severe AE flares should be managed with topical corticosteroids (TCSs). For mildto-moderate AE flares in sensitive skin areas, a topical calcineurin inhibitor (TCI) should be applied twice daily from the first signs of AE until complete resolution. Topical corticosteroids may be used when TCIs are unavailable. In non-sensitive skin areas, TCSs should be used for mild-to-moderate AE, but TCIs twice daily may be considered. Proactive maintenance treatment with low-dose TCI or TCS 2-3 times weekly and the liberal use of emollients is recommended for patients with recurrent flares. Conclusions: This algorithm aims to simplify treatment of paediatric AE, optimising clinical outcomes and reducing disease burden. This approach excludes treatment of patients with severe AE, who should be referred to specialist care. Emphasis has been given to the importance of general skincare, patient education and the topical anti-inflammatory medications available in South Africa (TCSs and TCIs).
- 1 January 2020
- Published by AOSIS in South African Family Practice
- Vol. 62 (1) , 9-e9
Open AccessPaediatric atopic eczema (atopic dermatitis) in South Africa: A practical algorithm for the management of mild-to-moderate disease in daily clinical practice
Background: Atopic eczema (AE) is a chronic, highly pruritic, inflammatory skin condition with increasing prevalence worldwide. Atopic eczema mostly affects children, impairing quality of life with poor disease control leading to progression of other atopic disorders. As most patients in South Africa have no access to specialist healthcare, a practical approach is needed for the management of mild-to-moderate AE in paediatric patients for daily clinical practice. Methods: A panel of experts in AE convened to develop a practical algorithm for the management of AE for children and adolescents in South Africa. Results: Regular moisturising with an oil-based emollient remains the mainstay of AE treatment. Severe AE flares should be managed with topical corticosteroids (TCSs). For mildto-moderate AE flares in sensitive skin areas, a topical calcineurin inhibitor (TCI) should be applied twice daily from the first signs of AE until complete resolution. Topical corticosteroids may be used when TCIs are unavailable. In non-sensitive skin areas, TCSs should be used for mild-to-moderate AE, but TCIs twice daily may be considered. Proactive maintenance treatment with low-dose TCI or TCS 2-3 times weekly and the liberal use of emollients is recommended for patients with recurrent flares. Conclusions: This algorithm aims to simplify treatment of paediatric AE, optimising clinical outcomes and reducing disease burden. This approach excludes treatment of patients with severe AE, who should be referred to specialist care. Emphasis has been given to the importance of general skincare, patient education and the topical anti-inflammatory medications available in South Africa (TCSs and TCIs).